A randomized trial of chemotherapy with carmustine, etoposide, cytarabine, and melphalan (BEAM) plus peripheral stem cell transplantation (PBSCT) vs single-agent high-dose chemotherapy followed by BEAM plus PBSCT in patients with relapsed Hodgkin's disease (HD-R2)

Author: Glossmann J.-P.   Josting A.   Pfistner B.   Paulus U.   Engert A.  

Publisher: Springer Publishing Company

ISSN: 0939-5555

Source: Annals of Hematology, Vol.81, Iss.8, 2002-08, pp. : 424-429

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content